Measuring treatment response to advance precision medicine for multiple sclerosis

Diagnosis and management of multiple sclerosis: MRI in clinical practice

(2020) Valentina Tomassini et al.   JOURNAL OF NEUROLOGY

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring

(2020) Peter A Calabresi et al.   Multiple Sclerosis Journal

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

(2019) Jens Kuhle et al.   NEUROLOGY

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS

(2019) Maria Pia Sormani et al.   Annals of Clinical and Translational Neurology

MS Relapses Contribute to Long Term Disability

(2019) Thomas F. Scott et al.   ACTA NEUROLOGICA SCANDINAVICA

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS

(2019) Katja Akgün et al.   Neurology-Neuroimmunology & Neuroinflammation

Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood

(2019) Robert Hendricks et al.   Bioanalysis

Serum NfL levels should be used to monitor multiple sclerosis evolution – Yes

(2019) David Leppert et al.   Multiple Sclerosis Journal

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

(2018) Christian Barro et al.   BRAIN

Multiple Sclerosis

(2018) Daniel S. Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

A brief history of NEDA

(2018) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

The evolution of “No Evidence of Disease Activity” in multiple sclerosis

(2018) G. Lu et al.   Multiple Sclerosis and Related Disorders

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Multiple sclerosis

(2018) Massimo Filippi et al.   Nature Reviews Disease Primers

Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS

(2017) Laura E Baldassari et al.   Multiple Sclerosis Journal

Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS

(2017) Laura E Baldassari et al.   Multiple Sclerosis Journal

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

(2016) Jens Kuhle et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

Brain MRI atrophy quantification in MS

(2016) Maria A. Rocca et al.   NEUROLOGY

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

The Multiple Sclerosis Functional Composite: A clinically meaningful measure of disability

(2015) C. H. Polman et al.   NEUROLOGY

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis

(2014) Sandra Meyer-Moock et al.   BMC Neurology

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

(2013) Angela Vidal-Jordana et al.   Multiple Sclerosis Journal

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Assessing disability progression with the Multiple Sclerosis Functional Composite

(2009) RA Rudick et al.   Multiple Sclerosis Journal

Gray matter atrophy in multiple sclerosis: A longitudinal study

(2008) Elizabeth Fisher et al.   ANNALS OF NEUROLOGY